Back to top

CHRS Maintained by Guggenheim -- Price Target Lowered to $10.00

CHRS Maintained by Guggenheim -- Price Target Lowered to $10.00

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Coherus Oncology, Inc. (CHRS)